{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T02:01:12Z","timestamp":1794621672285,"version":"4.9.1"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T00:00:00Z","timestamp":1712275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T00:00:00Z","timestamp":1712275200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Chronic migraine is a highly debilitating condition that is often difficult to manage, particularly in the presence of medication overuse headache. Drugs targeting the calcitonin gene-related peptide (CGRP), or its receptor have shown promising results in treating this disorder.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We searched Pubmed and Embase to identify randomized clinical trials and real-world studies reporting on the use of medication targeting the calcitonin gene-related peptide in patients with chronic migraine.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 270 records were identified. Nineteen studies qualified for the qualitative analysis. Most studies reported on monoclonal antibodies targeting CGRP (anti-CGRP mAbs), that overall prove to be effective in decreasing monthly migraine days by half in about 27.6\u201361.4% of the patients. Conversion from chronic to episodic migraine was seen in 40.88% of the cases, and 29\u201388% of the patients stopped medication overuse. Obesity seems to be the main negative predictor of response to anti-CGRP mAbs. There is no evidence to suggest the superiority of one anti-CGRP mAb. Despite the lack of strong evidence, the combination of anti-CGRP medication with onabotulinumtoxinA in chronic migraine is likely to bring benefits for resistant cases. Atogepant is the first gepant to demonstrate a significant decrease in monthly migraine days compared to placebo in a recent trial. Further, anti-CGRP mAb and gepants have a good safety profile.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>There is strong evidence from randomized trials and real-world data to suggest that drugs targeting CGRP are a safe and effective treatment for chronic migraine.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s10194-024-01753-y","type":"journal-article","created":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T23:01:51Z","timestamp":1712271711000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":69,"title":["CGRP-targeted medication in chronic migraine - systematic review"],"prefix":"10.1186","volume":"25","author":[{"given":"Renato","family":"Oliveira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Gil-Gouveia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1933-4049","authenticated-orcid":false,"given":"Francesca","family":"Puledda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,5]]},"reference":[{"issue":"8","key":"1753_CR1","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/nrneurol.2016.93","volume":"12","author":"A May","year":"2016","unstructured":"May A, Schulte LH (2016) Chronic migraine: risk factors, mechanisms and treatment. Nat Rev Neurol 12(8):455\u2013464","journal-title":"Nat Rev Neurol"},{"issue":"4","key":"1753_CR2","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.ncl.2019.06.001","volume":"37","author":"RC Burch","year":"2019","unstructured":"Burch RC, Buse DC, Lipton RB, Migraine (2019) Epidemiology, Burden, and Comorbidity. Neurol Clin 37(4):631\u2013649","journal-title":"Neurol Clin"},{"issue":"1","key":"1753_CR3","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s10194-018-0875-x","volume":"19","author":"N Vandenbussche","year":"2018","unstructured":"Vandenbussche N, Laterza D, Lisicki M, Lloyd J, Lupi C, Tischler H et al (2018) Medication-overuse headache: a widely recognized entity amidst ongoing debate. J Headache Pain 19(1):50","journal-title":"J Headache Pain"},{"issue":"1","key":"1753_CR4","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s10194-020-1084-y","volume":"21","author":"DC Buse","year":"2020","unstructured":"Buse DC, Reed ML, Fanning KM, Bostic R, Dodick DW, Schwedt TJ et al (2020) Comorbid and co-occurring conditions in migraine and associated risk of increasing headache pain intensity and headache frequency: results of the migraine in America symptoms and treatment (MAST) study. J Headache Pain 21(1):23","journal-title":"J Headache Pain"},{"issue":"10","key":"1753_CR5","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/nrneurol.2016.124","volume":"12","author":"HC Diener","year":"2016","unstructured":"Diener HC, Holle D, Solbach K, Gaul C (2016) Medication-overuse headache: risk factors, pathophysiology and management. Nat Rev Neurol 12(10):575\u2013583","journal-title":"Nat Rev Neurol"},{"issue":"11","key":"1753_CR6","first-page":"e19210","volume":"13","author":"HA Al Ghadeer","year":"2021","unstructured":"Al Ghadeer HA, AlSalman SA, Albaqshi FM, Alsuliman SR, Alsowailem FA, Albusror HA et al (2021) Quality of life and disability among Migraine patients: a single-center study in AlAhsa, Saudi Arabia. Cureus 13(11):e19210","journal-title":"Cureus"},{"key":"1753_CR7","doi-asserted-by":"crossref","unstructured":"Buse DC, Scher AI, Dodick DW, Reed ML, Fanning KM, Manack Adams A et al (2016) Impact of Migraine on the Family: Perspectives of People With Migraine and Their Spouse\/Domestic Partner in the CaMEO Study. Mayo Clin Proc. ;S0025-6196(16)00126-9","DOI":"10.1016\/j.mayocp.2016.02.013"},{"key":"1753_CR8","doi-asserted-by":"crossref","unstructured":"Schytz HW, Amin FM, Jensen RH, Carlsen L, Maarbjerg S, Lund N et al (2020) Reference programme: diagnosis and treatment of headache disorders and facial pain. Danish Headache Society, 3rd edition, J Headache Pain. 2021;22(1):22","DOI":"10.1186\/s10194-021-01228-4"},{"issue":"1","key":"1753_CR9","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s10194-019-1038-4","volume":"20","author":"EC Agostoni","year":"2019","unstructured":"Agostoni EC, Barbanti P, Calabresi P, Colombo B, Cortelli P, Frediani F et al (2019) Current and emerging evidence-based treatment options in chronic migraine: a narrative review. J Headache Pain 20(1):92","journal-title":"J Headache Pain"},{"issue":"6","key":"1753_CR10","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1177\/0333102414547138","volume":"35","author":"Z Hepp","year":"2015","unstructured":"Hepp Z, Dodick DW, Varon SF, Gillard P, Hansen RN, Devine EB (2015) Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia Int J Headache 35(6):478\u2013488","journal-title":"Cephalalgia Int J Headache"},{"issue":"7","key":"1753_CR11","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1111\/j.1533-2500.2012.00530.x","volume":"12","author":"A Berger","year":"2012","unstructured":"Berger A, Bloudek LM, Varon SF, Oster G (2012) Adherence with migraine prophylaxis in clinical practice. Pain Pract off J World Inst Pain 12(7):541\u2013549","journal-title":"Pain Pract off J World Inst Pain"},{"issue":"9","key":"1753_CR12","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1136\/jnnp-2013-307149","volume":"86","author":"SD Silberstein","year":"2015","unstructured":"Silberstein SD, Dodick DW, Aurora SK, Diener HC, DeGryse RE, Lipton RB et al (2015) Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT. J Neurol Neurosurg Psychiatry 86(9):996\u20131001","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"1753_CR13","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s40122-021-00264-x","volume":"10","author":"AM Blumenfeld","year":"2021","unstructured":"Blumenfeld AM, Frishberg BM, Schim JD, Iannone A, Schneider G, Yedigarova L et al (2021) Real-world evidence for control of chronic migraine patients receiving CGRP monoclonal antibody Therapy added to OnabotulinumtoxinA: a Retrospective Chart Review. Pain Ther 10(2):809\u2013826","journal-title":"Pain Ther"},{"key":"1753_CR14","doi-asserted-by":"crossref","unstructured":"T S, K B, A T. Calcitonin gene relating peptide inhibitors in combination for migraine treatment: A mini-review. Front Pain Res Lausanne Switz [Internet]. (2023) Mar 17 [cited 2024 Jan 7];4. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/37006413\/","DOI":"10.3389\/fpain.2023.1130239"},{"issue":"3","key":"1753_CR15","doi-asserted-by":"publisher","first-page":"033310242211502","DOI":"10.1177\/03331024221150235","volume":"43","author":"A Alpuente","year":"2023","unstructured":"Alpuente A, Torres-Ferrus M, Terwindt GM (2023) Preventive CGRP-targeted therapies for chronic migraine with and without medication-overuse headache. Cephalalgia 43(3):033310242211502","journal-title":"Cephalalgia"},{"issue":"1","key":"1753_CR16","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s10194-022-01431-x","volume":"23","author":"S Sacco","year":"2022","unstructured":"Sacco S, Amin FM, Ashina M, Bendtsen L, Deligianni CI, Gil-Gouveia R et al (2022) European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention \u2013\u20092022 update. J Headache Pain 23(1):67","journal-title":"J Headache Pain"},{"issue":"5","key":"1753_CR17","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.ijsu.2010.02.007","volume":"8","author":"D Moher","year":"2010","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group (2010) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg Lond Engl 8(5):336\u2013341","journal-title":"Int J Surg Lond Engl"},{"key":"1753_CR18","doi-asserted-by":"publisher","unstructured":"Lipton RB, Goadsby PJ, Smith J, Schaeffler BA, Biondi DM, Hirman J et al Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. Neurology [Internet]. 2020 Mar 31 [cited 2024 Jan 7];94(13). Available from: https:\/\/www.neurology.org\/doi\/https:\/\/doi.org\/10.1212\/WNL.0000000000009169","DOI":"10.1212\/WNL.0000000000009169"},{"issue":"7","key":"1753_CR19","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1111\/head.14169","volume":"61","author":"F Sakai","year":"2021","unstructured":"Sakai F, Suzuki N, Kim BK, Igarashi H, Hirata K, Takeshima T et al (2021) Efficacy and safety of fremanezumab for chronic migraine prevention: Multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients. Headache 61(7):1092\u20131101","journal-title":"Headache"},{"issue":"24","key":"1753_CR20","doi-asserted-by":"publisher","first-page":"e2211","DOI":"10.1212\/WNL.0000000000006640","volume":"91","author":"HC Detke","year":"2018","unstructured":"Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK (2018) Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology 91(24):e2211\u2013e2221","journal-title":"Neurology"},{"issue":"6","key":"1753_CR21","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1474-4422(17)30083-2","volume":"16","author":"S Tepper","year":"2017","unstructured":"Tepper S, Ashina M, Reuter U, Brandes JL, Dole\u017eil D, Silberstein S et al (2017) Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol 16(6):425\u2013434","journal-title":"Lancet Neurol"},{"issue":"22","key":"1753_CR22","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa1709038","volume":"377","author":"SD Silberstein","year":"2017","unstructured":"Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T et al (2017) Fremanezumab for the Preventive treatment of chronic migraine. N Engl J Med 377(22):2113\u20132122","journal-title":"N Engl J Med"},{"issue":"2","key":"1753_CR23","first-page":"1273","volume":"43","author":"U Pensato","year":"2022","unstructured":"Pensato U, Baraldi C, Favoni V, Cainazzo MM, Torelli P, Querzani P et al (2022) Real-life assessment of erenumab in refractory chronic migraine with medication overuse headache. Neurol Sci off J Ital Neurol Soc Ital Soc Clin Neurophysiol 43(2):1273\u20131280","journal-title":"Neurol Sci off J Ital Neurol Soc Ital Soc Clin Neurophysiol"},{"issue":"9","key":"1753_CR24","first-page":"5759","volume":"43","author":"M Curone","year":"2022","unstructured":"Curone M, Tullo V, Didier HA, Bussone G (2022) Overview on effectiveness of erenumab, fremanezumab, and galcanezumab in reducing medication overuse headache in chronic migraine patients. Neurol Sci off J Ital Neurol Soc Ital Soc Clin Neurophysiol 43(9):5759\u20135761","journal-title":"Neurol Sci off J Ital Neurol Soc Ital Soc Clin Neurophysiol"},{"issue":"1","key":"1753_CR25","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s10194-020-01143-0","volume":"21","author":"A Russo","year":"2020","unstructured":"Russo A, Silvestro M, Scotto di Clemente F, Trojsi F, Bisecco A, Bonavita S et al (2020) Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience. J Headache Pain 21(1):69","journal-title":"J Headache Pain"},{"issue":"1","key":"1753_CR26","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s10194-020-01127-0","volume":"21","author":"G Lambru","year":"2020","unstructured":"Lambru G, Hill B, Murphy M, Tylova I, Andreou AP (2020) A prospective real-world analysis of erenumab in refractory chronic migraine. J Headache Pain 21(1):61","journal-title":"J Headache Pain"},{"issue":"2","key":"1753_CR27","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s40263-021-00893-y","volume":"36","author":"LF Iannone","year":"2022","unstructured":"Iannone LF, Fattori D, Benemei S, Chiarugi A, Geppetti P, De Cesaris F (2022) Long-term effectiveness of three Anti-CGRP monoclonal antibodies in resistant chronic migraine patients based on the MIDAS score. CNS Drugs 36(2):191\u2013202","journal-title":"CNS Drugs"},{"issue":"20","key":"1753_CR28","doi-asserted-by":"publisher","first-page":"e2309","DOI":"10.1212\/WNL.0000000000007497","volume":"92","author":"SJ Tepper","year":"2019","unstructured":"Tepper SJ, Diener HC, Ashina M, Brandes JL, Friedman DI, Reuter U et al (2019) Erenumab in chronic migraine with medication overuse: subgroup analysis of a randomized trial. Neurology 92(20):e2309\u2013e2320","journal-title":"Neurology"},{"key":"1753_CR29","doi-asserted-by":"publisher","first-page":"1129439","DOI":"10.3389\/fneur.2023.1129439","volume":"14","author":"AV Krymchantowski","year":"2023","unstructured":"Krymchantowski AV, Jevoux C, Krymchantowski AG, Silva-N\u00e9to RP (2023) Monoclonal antibodies for chronic migraine and medication overuse headache: a real-world study. Front Neurol 14:1129439","journal-title":"Front Neurol"},{"issue":"7","key":"1753_CR30","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1177\/03331024211067791","volume":"42","author":"U Pensato","year":"2022","unstructured":"Pensato U, Baraldi C, Favoni V, Mascarella D, Matteo E, Andrini G et al (2022) Detoxification vs non-detoxification before starting an anti-CGRP monoclonal antibody in medication overuse headache. Cephalalgia Int J Headache 42(7):645\u2013653","journal-title":"Cephalalgia Int J Headache"},{"issue":"1","key":"1753_CR31","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s10194-022-01498-6","volume":"23","author":"P Barbanti","year":"2022","unstructured":"Barbanti P, Egeo G, Aurilia C, Altamura C, d\u2019Onofrio F, Finocchi C et al (2022) Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients. J Headache Pain 23(1):138","journal-title":"J Headache Pain"},{"issue":"5","key":"1753_CR32","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1111\/ene.15260","volume":"29","author":"LF Iannone","year":"2022","unstructured":"Iannone LF, Fattori D, Benemei S, Chiarugi A, Geppetti P, De Cesaris F (2022) Predictors of sustained response and effects of the discontinuation of anti-calcitonin gene related peptide antibodies and reinitiation in resistant chronic migraine. Eur J Neurol 29(5):1505\u20131513","journal-title":"Eur J Neurol"},{"issue":"3","key":"1753_CR33","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1111\/ene.14102","volume":"27","author":"J Ailani","year":"2020","unstructured":"Ailani J, Pearlman E, Zhang Q, Nagy AJ, Schuh K, Aurora SK (2020) Positive response to galcanezumab following treatment failure to onabotulinumtoxinA in patients with migraine: post hoc analyses of three randomized double-blind studies. Eur J Neurol 27(3):542\u2013549","journal-title":"Eur J Neurol"},{"issue":"7","key":"1753_CR34","doi-asserted-by":"publisher","first-page":"2378","DOI":"10.1111\/ene.14828","volume":"28","author":"A Alpuente","year":"2021","unstructured":"Alpuente A, Gallardo VJ, Caronna E, Torres-Ferr\u00fas M, Pozo-Rosich P (2021) Partial and nonresponders to onabotulinumtoxinA can benefit from anti-CGRP monoclonal antibodies preventive treatment: a real-world evidence study. Eur J Neurol 28(7):2378\u20132382","journal-title":"Eur J Neurol"},{"issue":"2","key":"1753_CR35","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s40263-022-00983-5","volume":"37","author":"LF Iannone","year":"2023","unstructured":"Iannone LF, Fattori D, Marangoni M, Benemei S, Chiarugi A, Geppetti P et al (2023) Switching OnabotulinumtoxinA to monoclonal Anti-CGRP antibodies in drug-resistant chronic migraine. CNS Drugs 37(2):189\u2013202","journal-title":"CNS Drugs"},{"issue":"10404","key":"1753_CR36","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/S0140-6736(23)01049-8","volume":"402","author":"P Pozo-Rosich","year":"2023","unstructured":"Pozo-Rosich P, Ailani J, Ashina M, Goadsby PJ, Lipton RB, Reuter U et al (2023) Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Lond Engl 402(10404):775\u2013785","journal-title":"Lancet Lond Engl"},{"issue":"1","key":"1753_CR37","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s10194-020-01102-9","volume":"21","author":"R Ornello","year":"2020","unstructured":"Ornello R, Casalena A, Frattale I, Gabriele A, Affaitati G, Giamberardino MA et al (2020) Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy. J Headache Pain 21(1):32","journal-title":"J Headache Pain"},{"issue":"3","key":"1753_CR38","doi-asserted-by":"publisher","first-page":"333102423115216","DOI":"10.1177\/03331024231152169","volume":"43","author":"R Messina","year":"2023","unstructured":"Messina R, Huessler EM, Puledda F, Haghdoost F, Lebedeva ER, Diener HC (2023) Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: a systematic review and network meta-analysis. Cephalalgia Int J Headache 43(3):3331024231152169","journal-title":"Cephalalgia Int J Headache"},{"issue":"4","key":"1753_CR39","doi-asserted-by":"publisher","first-page":"333102423115936","DOI":"10.1177\/03331024231159366","volume":"43","author":"F Haghdoost","year":"2023","unstructured":"Haghdoost F, Puledda F, Garcia-Azorin D, Huessler EM, Messina R, Pozo-Rosich P (2023) Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: a systematic review and network meta-analysis of phase 3 randomised controlled trials. Cephalalgia Int J Headache 43(4):3331024231159366","journal-title":"Cephalalgia Int J Headache"},{"issue":"6","key":"1753_CR40","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1177\/0333102416650702","volume":"37","author":"CM Kopruszinski","year":"2017","unstructured":"Kopruszinski CM, Xie JY, Eyde NM, Remeniuk B, Walter S, Stratton J et al (2017) Prevention of stress- or nitric oxide donor-induced medication overuse headache by a calcitonin gene-related peptide antibody in rodents. Cephalalgia Int J Headache 37(6):560\u2013570","journal-title":"Cephalalgia Int J Headache"},{"issue":"1","key":"1753_CR41","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/1129-2377-14-93","volume":"14","author":"S Feistel","year":"2013","unstructured":"Feistel S, Albrecht S, Messlinger K (2013) The calcitonin gene-related peptide receptor antagonist MK-8825 decreases spinal trigeminal activity during nitroglycerin infusion. J Headache Pain 14(1):93","journal-title":"J Headache Pain"},{"issue":"9","key":"1753_CR42","doi-asserted-by":"publisher","first-page":"2681","DOI":"10.1093\/brain\/awaa211","volume":"143","author":"C Saengjaroentham","year":"2020","unstructured":"Saengjaroentham C, Strother LC, Dripps I, Sultan Jabir MR, Pradhan A, Goadsby PJ et al (2020) Differential medication overuse risk of novel anti-migraine therapeutics. Brain J Neurol 143(9):2681\u20132688","journal-title":"Brain J Neurol"},{"issue":"7","key":"1753_CR43","doi-asserted-by":"publisher","first-page":"3654","DOI":"10.1007\/s00415-023-11706-1","volume":"270","author":"F Puledda","year":"2023","unstructured":"Puledda F, Silva EM, Suwanlaong K, Goadsby PJ (2023) Migraine: from pathophysiology to treatment. J Neurol 270(7):3654\u20133666","journal-title":"J Neurol"},{"issue":"4\u20135","key":"1753_CR44","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1177\/03331024211048765","volume":"42","author":"LH Overeem","year":"2022","unstructured":"Overeem LH, Peikert A, Hofacker MD, Kamm K, Ruscheweyh R, Gendolla A et al (2022) Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: a multi-center retrospective cohort study. Cephalalgia Int J Headache 42(4\u20135):291\u2013301","journal-title":"Cephalalgia Int J Headache"},{"issue":"11","key":"1753_CR45","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1212\/WNL.0000000000207292","volume":"101","author":"P Barbanti","year":"2023","unstructured":"Barbanti P, Aurilia C, Egeo G, Torelli P, Proietti S, Cevoli S et al (2023) Late response to Anti-CGRP monoclonal antibodies in migraine: a Multicenter prospective observational study. Neurology 101(11):482\u2013488","journal-title":"Neurology"},{"issue":"3","key":"1753_CR46","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S1474-4422(21)00409-9","volume":"21","author":"L Al-Hassany","year":"2022","unstructured":"Al-Hassany L, Goadsby PJ, Danser AHJ, MaassenVanDenBrink A (2022) Calcitonin gene-related peptide-targeting drugs for migraine: how pharmacology might inform treatment decisions. Lancet Neurol 21(3):284\u2013294","journal-title":"Lancet Neurol"},{"key":"1753_CR47","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.cophys.2019.10.013","volume":"11","author":"G Dussor","year":"2019","unstructured":"Dussor G (2019) New discoveries in migraine mechanisms and therapeutic targets. Curr Opin Physiol 11:116\u2013124","journal-title":"Curr Opin Physiol"},{"issue":"10","key":"1753_CR48","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1177\/0333102419844711","volume":"39","author":"KW Johnson","year":"2019","unstructured":"Johnson KW, Morin SM, Wroblewski VJ, Johnson MP (2019) Peripheral and central nervous system distribution of the CGRP neutralizing antibody [125I] galcanezumab in male rats. Cephalalgia Int J Headache 39(10):1241\u20131248","journal-title":"Cephalalgia Int J Headache"},{"issue":"6","key":"1753_CR49","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1177\/0333102420981688","volume":"41","author":"CM Kopruszinski","year":"2021","unstructured":"Kopruszinski CM, Turnes JM, Swiokla J, Weinstein TJ, Schwedt TJ, Dodick DW et al (2021) CGRP monoclonal antibody prevents the loss of diffuse noxious inhibitory controls (DNIC) in a mouse model of post-traumatic headache. Cephalalgia Int J Headache 41(6):749\u2013759","journal-title":"Cephalalgia Int J Headache"},{"issue":"1","key":"1753_CR50","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s10194-020-01130-5","volume":"21","author":"S Sacco","year":"2020","unstructured":"Sacco S, Braschinsky M, Ducros A, Lampl C, Little P, van den Brink AM et al (2020) European headache federation consensus on the definition of resistant and refractory migraine: developed with the endorsement of the European Migraine & Headache Alliance (EMHA). J Headache Pain 21(1):76","journal-title":"J Headache Pain"},{"issue":"7","key":"1753_CR51","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1111\/head.14153","volume":"61","author":"J Ailani","year":"2021","unstructured":"Ailani J, Burch RC, Robbins MS, Board of Directors of the American Headache Society (2021) The American Headache Society Consensus Statement: update on integrating new migraine treatments into clinical practice. Headache 61(7):1021\u20131039","journal-title":"Headache"},{"issue":"7","key":"1753_CR52","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1111\/head.13849","volume":"60","author":"R Burstein","year":"2020","unstructured":"Burstein R, Blumenfeld AM, Silberstein SD, Manack Adams A, Brin MF (2020) Mechanism of action of OnabotulinumtoxinA in chronic migraine: a narrative review. Headache 60(7):1259\u20131272","journal-title":"Headache"},{"issue":"11","key":"1753_CR53","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1177\/0333102419873675","volume":"39","author":"A Melo-Carrillo","year":"2019","unstructured":"Melo-Carrillo A, Strassman AM, Schain AJ, Noseda R, Ashina S, Adams A et al (2019) Exploring the effects of extracranial injections of botulinum toxin type A on prolonged intracranial meningeal nociceptors responses to cortical spreading depression in female rats. Cephalalgia Int J Headache 39(11):1358\u20131365","journal-title":"Cephalalgia Int J Headache"},{"issue":"4","key":"1753_CR54","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1111\/head.14294","volume":"62","author":"MD Ferrari","year":"2022","unstructured":"Ferrari MD, Zuurbier KWM, Barash S, Ning X, Cohen JM (2022) Fremanezumab in individuals with chronic migraine who had inadequate response to onabotulinumtoxinA and topiramate or valproic acid. Headache 62(4):530\u2013533","journal-title":"Headache"},{"issue":"10","key":"1753_CR55","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1177\/0333102418788347","volume":"38","author":"M Ashina","year":"2018","unstructured":"Ashina M, Tepper S, Brandes JL, Reuter U, Boudreau G, Dolezil D et al (2018) Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: a subgroup analysis of a randomized, double-blind, placebo-controlled study. Cephalalgia Int J Headache 38(10):1611\u20131621","journal-title":"Cephalalgia Int J Headache"},{"issue":"12","key":"1753_CR56","doi-asserted-by":"publisher","first-page":"847","DOI":"10.3390\/toxins14120847","volume":"14","author":"AA Argyriou","year":"2022","unstructured":"Argyriou AA, Dermitzakis EV, Xiromerisiou G, Vikelis M (2022) OnabotulinumtoxinA Add-On to monoclonal Anti-CGRP antibodies in treatment-refractory chronic migraine. Toxins 14(12):847","journal-title":"Toxins"},{"issue":"12","key":"1753_CR57","first-page":"5373","volume":"42","author":"T Toni","year":"2021","unstructured":"Toni T, Tamanaha R, Newman B, Liang Y, Lee J, Carrazana E et al (2021) Effectiveness of dual migraine therapy with CGRP inhibitors and onabotulinumtoxinA injections: case series. Neurol Sci off J Ital Neurol Soc Ital Soc Clin Neurophysiol 42(12):5373\u20135376","journal-title":"Neurol Sci off J Ital Neurol Soc Ital Soc Clin Neurophysiol"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-024-01753-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-024-01753-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-024-01753-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T23:01:56Z","timestamp":1712271716000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-024-01753-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,5]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1753"],"URL":"https:\/\/doi.org\/10.1186\/s10194-024-01753-y","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,5]]},"assertion":[{"value":"12 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"NA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and Consent for publication"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"51"}}